The type of factor VIII deficient plasma used influences the performance of the Nijmegen modification of the Bethesda assay for factor VIII inhibitors

Thrombosis and Haemostasis

Volumn 86, Issue 6, 2001, Pages 1435-1439

  Verbruggen, B ^a   Giles, A ^a   Samis, J ^a   Verbeek, K ^a   Mensink, E ^a   Novakova I ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Factor VIII inhibitors assay; Standardisation

Indexed keywords

BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; VON WILLEBRAND FACTOR;

ANALYZER; ARTICLE; ASSAY; BLOOD ANALYSIS; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTAMINATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG SCREENING; HUMAN; LABORATORY TEST; PLASMA; PRIORITY JOURNAL; RELIABILITY; SENSITIVITY AND SPECIFICITY; STANDARDIZATION;

EID: 0035655653     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616765     Document Type: Article

References (12)

1. Haemophiliacs with factor VIII inhibitors in Finland: Prevalence, incidence and outcome
2. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs
3. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII
4. Recombinant factor VIII for the treatment of previously untreated patients with haemophilia A
5. How do some haemophiliacs develop inhibitors?
6. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: Improved specificity and reliability
7. A more uniform measurement of factor VIII-inhibitors
8. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada
9. Human antibodies with specificity for the C2 domain of factor VIII are derived from germline genes
10. "Factor V"
11. A method for assaying von Willebrand factor (ristocetin cofactor)
12. An artificial 'haemophilic' plasma for one-stage factor-VIII assay